Health

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Investor webcast to be held on Monday November 3, 2025 at 8:00 am EST November 02, 2025 19:00 ET  |…

2 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

November 02, 2025 19:00 ET  | Source: HUTCHMED (China) Limited — HUTCHMED unveils its innovative ATTC platform, potentially providing precision…

2 months ago

Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05

REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…

2 months ago

Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business

COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and…

2 months ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

October 31, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) --…

2 months ago

Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service

October 31, 2025 16:05 ET  | Source: Clover Health Investments, Corp. WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover…

2 months ago

Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…

2 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

2 months ago

Cellectis to Report Third Quarter Financial Results on November 7, 2025

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…

2 months ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…

2 months ago